BRPI0509497A - seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais - Google Patents

seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais

Info

Publication number
BRPI0509497A
BRPI0509497A BRPI0509497-6A BRPI0509497A BRPI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A BR PI0509497 A BRPI0509497 A BR PI0509497A
Authority
BR
Brazil
Prior art keywords
modulating
polypeptide sequence
viral proteins
immunosuppressive effect
protein
Prior art date
Application number
BRPI0509497-6A
Other languages
English (en)
Inventor
Martial Renard
Marianne Mangeney
Therry Heidmann
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Publication of BRPI0509497A publication Critical patent/BRPI0509497A/pt
Publication of BRPI0509497B1 publication Critical patent/BRPI0509497B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SEQUêNCIA DE POLIPEPTìDEOS ENVOLVIDA NA MODULAçãO DO EFEITO IMUNOSUPRESSOR DE PROTEìNAS VIRAIS A presente invenção se refere a um polipeptídeo tendo uma seqüência de 7 a 20 resíduos de aminoácido, que é capaz de modular as propriedades imunosupressoras de uma proteína viral, ou um fragmento desta, contra o hospedeiro no qual ela é expressa (seqüência de imunosupressão-modulatória) quando substitui a seqüência homóloga de referida proteína viral ou fragmento, referido polipeptídeo compreendendo a seqüência de amino ácido de consenso seguinte mínimo: X1 Y9 Y10 Y11 CY12 X2(subscritos) no qual X1 e X2 são selecionados para impactarem nas referidas propriedades imunosupressora, e Y9 a Y12 representam resíduos de aminoácido variáveis.
BRPI0509497-6A 2004-03-30 2005-03-30 Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais BRPI0509497B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838.4 2004-03-30
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (2)

Publication Number Publication Date
BRPI0509497A true BRPI0509497A (pt) 2007-09-11
BRPI0509497B1 BRPI0509497B1 (pt) 2022-07-19

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509497-6A BRPI0509497B1 (pt) 2004-03-30 2005-03-30 Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais

Country Status (14)

Country Link
US (2) US8178657B2 (pt)
EP (1) EP1732585B1 (pt)
JP (1) JP5060284B2 (pt)
CN (1) CN1961001B (pt)
AT (1) ATE472334T1 (pt)
AU (1) AU2005229411B2 (pt)
BR (1) BRPI0509497B1 (pt)
CA (1) CA2561376C (pt)
DE (1) DE602005022056D1 (pt)
ES (1) ES2347445T3 (pt)
IL (1) IL178205A (pt)
MX (1) MXPA06011272A (pt)
WO (1) WO2005095442A1 (pt)
ZA (1) ZA200608178B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
ATE538802T1 (de) 2005-03-30 2012-01-15 Viroxis Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
JP5624994B2 (ja) 2009-01-09 2014-11-12 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 新たなレセプター結合性リガンド、生物学的対象の細胞の検出におけるその使用
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
BR112014001287B1 (pt) * 2011-07-20 2020-12-08 Centre National De La Recherche Scientifique vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
CA2856180C (en) 2011-12-07 2022-09-06 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
WO2014195510A1 (en) * 2013-06-07 2014-12-11 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CN108368155A (zh) * 2015-10-01 2018-08-03 爱姆维恩公司 人源性免疫抑制蛋白和肽作为药物的应用
WO2019043127A1 (en) 2017-09-01 2019-03-07 Inprother Aps VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
EP4277704A1 (en) * 2021-01-13 2023-11-22 Viroxis Measles-hiv or measles-htlv vaccine
CN121752289A (zh) 2023-04-21 2026-03-27 盈珀治疗有限公司 表面展示抗原的改善表达

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
DE68929419T2 (de) 1988-12-13 2003-04-03 Colorado State University Research Foundation, Fort Collins Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
AU2002230758A1 (en) * 2000-12-11 2002-06-24 Tufts University Treatment and prevention of EBV infection and EBV-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US20080008683A1 (en) 2008-01-10
ES2347445T3 (es) 2010-10-29
JP2008506357A (ja) 2008-03-06
ZA200608178B (en) 2008-10-29
EP1732585B1 (en) 2010-06-30
EP1732585A1 (en) 2006-12-20
WO2005095442A8 (en) 2006-11-02
US20120189647A1 (en) 2012-07-26
ATE472334T1 (de) 2010-07-15
CA2561376C (en) 2016-06-21
US8178657B2 (en) 2012-05-15
AU2005229411B2 (en) 2010-11-18
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
AU2005229411A1 (en) 2005-10-13
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
CN1961001B (zh) 2012-09-05
IL178205A0 (en) 2006-12-31
US8597657B2 (en) 2013-12-03
CN1961001A (zh) 2007-05-09
CA2561376A1 (en) 2005-10-13
DE602005022056D1 (de) 2010-08-12
IL178205A (en) 2015-05-31

Similar Documents

Publication Publication Date Title
IL178205A0 (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
BR112016015512A2 (pt) proteínas quiméricas de fator viii e suas utilizações
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
MX2013015323A (es) Polipeptidos de fusion de serpina y metodos de uso de los mismos.
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
PH12022552935A1 (en) Stabilized coronavirus spike protein fusion proteins
IL187321A (en) Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
ATE463512T1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
JOP20240256A1 (ar) بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
PH12022553417A1 (en) Stabilized corona virus spike protein fusion proteins
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: INSTITUT GUSTAVE ROUSSY (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.